Trials / Active Not Recruiting
Active Not RecruitingNCT05576922
Collagen Matrix + rhPDGF-BB vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences
Xenogeneic Collagen Matrix Loaded With rhPDGF-BB vs Autogenous Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences: A Randomized, Controlled, Clinical, Trial
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Harvard Medical School (HMS and HSDM) · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The study aims at comparing two different approaches for the treatment of implant esthetic complications (peri-implant soft tissue dehiscences): autogenous connective tissue graft vs collagen matrix + recombinant human platelet derived growth factor-BB
Detailed description
The present randomized clinical trial aims at investigating two approaches (autogenous connective tissue graft vs collagen matrix + recombinant human platelet derived growth factor-BB) when performed in combination with the prosthetic-surgical approach for the treatment of peri-implant soft tissue dehiscences. Clinical, volumetric, ultrasonographic and patient-reported outcomes will be evaluated at different time points up to 1 year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Prosthetic-surgical approach + autogenous graft | Coronally advanced flap with an autogenous graft (CTG) |
| OTHER | Prosthetic-surgical approach + graft substitute | Coronally advanced flap with a graft substitute (collagen matrix and rhPDGF-BB) |
Timeline
- Start date
- 2023-01-04
- Primary completion
- 2025-10-20
- Completion
- 2025-10-21
- First posted
- 2022-10-13
- Last updated
- 2025-04-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05576922. Inclusion in this directory is not an endorsement.